SynthesisFrontiers in endocrinology2025
A meta-analysis of the prognostic value of the TyG index in heart failure.
Synthesis in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of the triglyceride-glucose index with the risk of sarcopenia: a meta-analysis with clinical implications.BMC endocrine disorders · 2026Pooled it
- The triglyceride-glucose index as a predictor of cardiovascular disease: an umbrella review of meta-analyses.Annals of medicine and surgery (2012) · 2026Article
- Ceramides as Biomarkers and Pharmacological Targets in Heart Failure Pathophysiology.Biomolecules · 2026Review
- Association between triglyceride-glucose index and related indicators with heart failure-related mortality in individuals with early-stage cardiovascular-kidney-metabolic syndrome.Cardiovascular diabetology · 2026Article
- From Metabolism to Mind: The Cardio-Metabolic-Brain Axis and the Role of Insulin Resistance-A Review.Biomedicines · 2026Review
- Article
- Head-to-head comparison of stress hyperglycemia ratio versus triglyceride-glucose index for predicting mortality in heart failure: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Review on the Relationship Between TyG Index and CVD Incidence in Patients With T2DM With NAFLD.International journal of endocrinology · 2026Review
- Association between triglyceride-glucose index-a body shape index and atherosclerotic cardiovascular disease, and the modification effect of dietary patterns.Frontiers in nutrition · 2026Article
- The correlation between the triglyceride-glucose index and the odds of cervical cancer.Frontiers in oncology · 2026Article
- Associations between triglyceride-glucose-related indices and all-cause and cardiovascular mortality among individuals with atrial fibrillation and metabolic syndrome: a cohort study of the UK biobank.Cardiovascular diabetology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Heart failure (HF) is a serious cardiovascular disorder with a poor prognosis, which affects the quality of life and survival in patients. The triglyceride-glucose (TyG) index, a new biomarker for insulin resistance (IR) in the body, has attracted widespread attention from researchers investigating cardiovascular disease (CVD). This study was aimed at assessing the prognostic value of the TyG index in HF patients by a meta-analysis, thereby providing clinicians with a new predictive tool. Methods: PubMed, Cochrane, EMBASE, and Web of Science were searched for studies (from inception to March 2025) on the association of the TyG index with the prognosis of HF. Meta-analysis was conducted using Stata15. Such association was assessed using a random effects model in conjunction with the hazard ratio (HR) and its 95% confidence interval (CI). In addition, subgroup analysis, publication bias analysis, and sensitivity analysis were performed. Results: Nineteen studies were included with 44275 HF patients. A significant association was found between an increase in the TyG index and an increase in the risk of all-cause death (ACD) in HF patients (HR=1.70, 95% CI: 1.40-2.08, P<0.001). Increased TyG index predicted major adverse cardiovascular events (MACEs) (HR=2.37, 95% CI: 1.80-3.13, P<0.001) and cardiovascular death (CV death) (HR=1.63, 95% CI: 1.01-2.61, P<0.001). Subgroup analysis showed an association of increased TyG index with a poor prognosis regardless of ejection fraction, and the presence or absence of diabetes. Dose-response analysis showed no linear dose-response relationship (DRR) of the index with ACD, MACEs or CV death. Conclusion: The TyG index is closely associated with the prognosis of HF. Therefore, it can be used as a prognostic tool for the assessment of HF. A high TyG index may indicate a high risk of ACD and CV events. Therefore, monitoring of the TyG index is significant for risk assessment and management of HF patients. Future studies on the use of the TyG index in therapeutic decision-making for HF are needed. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42024562063.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.